For the pharma industry, the rise of healthcare content creators – both healthcare professionals (HCPs) and patients – ...

Jazz Pharmaceuticals has shared positive top-line results from a late-stage study evaluating its alkylating drug Zepzelca ...

Pfizer’s anti-tissue factor pathway inhibitor Hympavzi (marstacimab-hncq) has been approved by the US Food and Drug ...

Eli Lilly has shared one-year histologic outcomes from a phase 3 study of its interleukin-23p19 antagonist mirikizumab in ...

Patient Recruitment company, Innovative Trials, appointed new Finance and Business Services Director Innovative Trials have ...

Johnson & Johnson (J&J) has announced results from a real-world study comparing its Erleada (apalutamide) to Pfizer and ...

Inizio Medical has announced the appointment of Matt Wadyka as president, US medical affairs. In this newly created role, ...

Johnson & Johnson’s (J&J) investigational FcRn blocker nipocalimab has demonstrated sustained disease control in adolescents with the rare autoimmune disease generalised myasthenia gravis (gMG), ...

AstraZeneca (AZ) has entered into an exclusive licence agreement worth over $1.9bn to advance CSPC Pharmaceutical Group’s pre-clinical lipid-lowering therapy, strengthening the Anglo-Swedish drugmaker ...

Astellas Pharma and AviadoBio have entered into an exclusive option and licence agreement worth over $2bn for an ...

AbbVie has shared positive top-line results from a late-stage study of its investigational Parkinson’s disease (PD) drug in adults. The phase 3 TEMPO-1 trial evaluated two fixed doses of the D1/D5 ...

Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its anti-PD-1 therapy in head and neck cancer. The phase 3 KEYNOTE-689 trial has been ...